Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

In order to boost immune responses in persons in whom highly active antiretroviral therapy (HAART) was initiated within 120 days of the onset of symptoms of newly acquired human immunodeficiency virus type 1 (HIV-1) infection, we administered vaccines containing a canarypox virus vector, vCP1452, wi...

Descripción completa

Detalles Bibliográficos

Publicado en:	J Virol
Autores principales:	Jin, Xia, Ramanathan, Jr., Murugappan, Barsoum, Shady, Deschenes, Geoffrey R., Ba, Lei, Binley, James, Schiller, Daryl, Bauer, Daniel E., Chen, Donald C., Hurley, Arlene, Gebuhrer, Lucette, El Habib, Raphaelle, Caudrelier, Pierre, Klein, Michel, Zhang, Linqi, Ho, David D., Markowitz, Martin
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	American Society for Microbiology (ASM) 2002
Materias:	Vaccines and Antiviral Agents
Acceso en línea:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC135946/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11836398/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.76.5.2206-2216.2002
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!